Protective effects of catalpol on cardio-cerebrovascular diseases:A comprehensive review
10.1016/j.jpha.2023.06.010
- Author:
Zixi ZHANG
1
;
Yongguo DAI
;
Yichao XIAO
;
Qiming LIU
Author Information
1. Department of Cardiovascular Medicine,The Second Xiangya Hospital,Central South University,Changsha,Hunan,410011,China
- Keywords:
Catalpol;
Cardio-cerebrovascular diseases;
Anti-atherosclerosis;
Cerebrovascular protection;
Heart protection
- From:
Journal of Pharmaceutical Analysis
2023;13(10):1089-1101
- CountryChina
- Language:Chinese
-
Abstract:
Catalpol,an iridoid glucoside isolated from Rehmannia glutinosa,has gained attention due to its potential use in treating cardio-cerebrovascular diseases(CVDs).This extensive review delves into recent studies on catalpol's protective properties in relation to various CVDs,such as atherosclerosis,myocardial ischemia,infarction,cardiac hypertrophy,and heart failure.The review also explores the compound's anti-oxidant,anti-inflammatory,and anti-apoptotic characteristics,emphasizing the role of vital signaling pathways,including PGC-1a/TERT,PI3K/Akt,AMPK,Nrf2/HO-1,estrogen receptor(ER),Nox4/NF-κB,and GRP78/PERK.The article discusses emerging findings on catalpol's ability to alleviate diabetic cardiovascular complications,thrombosis,and other cardiovascular-related conditions.Although clinical studies specifically addressing catalpol's impact on CVDs are scarce,the compound's established safety and well-tolerated nature suggest that it could be a valuable treatment alternative for CVD patients.Further investigation into catalpol and related iridoid derivatives may unveil new opportunities for devising natural and efficacious CVD therapies.
